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A B S T R A C T
Background: A breadth of literature exists that explores the utilization of research evidence in policy
change processes. From this work, a number of studies suggest research evidence is applied to change
processes by policy change stakeholders primarily through instrumental, conceptual, and/or symbolic
applications, or is not used at all. Despite the expansiveness of research on policy change processes, a
deﬁcit exists in understanding the role of research evidence during change processes related to the
implementation of structural interventions for HIV prevention among injection drug users (IDU). This
study examined the role of research evidence in policy change processes for the implementation of
publicly funded syringe exchange services in three US cities: Baltimore, MD, Philadelphia, PA, and
Washington, DC.
Methods: In-depth qualitative interviews were conducted with key stakeholders (n = 29) from each of
the study cities. Stakeholders were asked about the historical, social, political, and scientiﬁc contexts in
their city during the policy change process. Interviews were transcribed and analyzed for common
themes pertaining to applications of research evidence.
Results: In Baltimore and Philadelphia, the typological approaches (instrumental and symbolic/
conceptual, respectively) to the applications of research evidence used by harm reduction proponents
contributed to the momentum for securing policy change for the implementation of syringe exchange
services. Applications of research evidence were less successful in DC because policymakers had
differing ideas about the implications of syringe exchange program implementation and because
opponents of policy change used evidence incorrectly or not at all in policy change discussions.
Conclusion: Typological applications of research evidence are useful for understanding policy change
processes, but their efﬁcacy falls short when sociopolitical factors complicate legislative processes. Advocates
for harm reduction may beneﬁt from understanding how to effectively integrate research evidence into policy
change processes in ways that confront the myriad of factors that inﬂuence policy change.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Public health literature suggests that policies should reﬂect
consideration of research evidence; unfortunately, the manifesta-
tion of evidence in policy processes is complicated by a number of
sociopolitical and structural factors that result in it not being used
to the extent that it could in theory (Brownson, Royer, Ewing, &
Mcbride, 2006; Davis & Howden-chapman, 1996; Edwards, 2005;
Frenk, 1992; Hanney, Gonzalez-Block, Buxton, & Kogan, 2003;* Corresponding author. Tel.: +1 859 338 1342.
E-mail address: seanallen@gwu.edu (S.T. Allen).
http://dx.doi.org/10.1016/j.drugpo.2015.04.008
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4.0/).Nutley, Walter, & Davies, 2003; Ritter, 2011; Trostle, Bronfman, &
Langer, 1999). Policymakers may struggle to implement evidence-
based policies while simultaneously addressing the priorities of
their electorate. In some cases, policymakers are presented with
research evidence that they cannot easily understand (e.g.,
information is presented using too much scientiﬁc jargon) or
utilize (e.g., information is provided at a time when opportunities
for policy change are not present) (Brownson et al., 2006;
Brownson, Chriqui, & Stamatakis, 2009; Mcbride et al., 2008).
Policy change related to the implementation of harm reduction
strategies – such as syringe exchange programs (SEPs) – has been
especially slow moving, a fact that is not surprising given the
stigmatization of injection drug users (IDU) (Ross & Darke, 1992)e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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politics of drug policy can be either ‘zero tolerance’ or ‘harm
reduction’. For the former, drug policy signiﬁes a moral statement
by government against drug use. . . . . .For harm reduction,
government’s role is to protect society from the consequences of
drug use, but not to eliminate drug use itself. . .’’ (Ritter, 2011).
Though policymakers may have varying opinions on the merits
and moral obligations of expanding services to meet the needs of
IDU, there is a body of research documenting the utility and cost-
effectiveness of implementing SEPs and other harm reduction
services for this population. Research shows that SEPs are effective
in reducing HIV incidence as well as injection-related practices
that increase HIV and HCV risk (Gibson et al., 2002; Kerr et al.,
2010; Ksobiech, 2003; Palmateer et al., 2010; Watters, Estilo, Clark,
& Lorvick, 1994; Wodak & Cooney, 2006; Wodak & Mcleod, 2008).
Unfortunately, legislative barriers, such as paraphernalia laws,
funding restrictions, and operational restrictions, impede the
widespread implementation of these programs. As the evidence of
beneﬁt continues to grow, harm reduction proponents are often
puzzled as to why policies do not align with the evidence that
shows the social, public health, and ﬁnancial beneﬁt of expanding
such services.
In efforts to confront the health disparities among the
estimated 15.9 million people who inject drugs globally (Mathers
et al., 2008), 86 countries have implemented SEPs (Harm Reduction
International, 2012). Unfortunately, access to harm reduction
services is not equal in all parts of the world and most low and
middle-income countries do not implement SEPs at coverage levels
necessary to stabilize and reverse HIV epidemics among IDU (Harm
Reduction International, 2012). For example, although it is
estimated that there are approximately 3,476,500 people (range:
2,540,000–4,543,500) in Eastern Europe who inject drugs (Harm
Reduction International, 2012), yet only 10% of IDU in this region
access SEPs (Stuikyte, Votyagov, & Pinkham, 2012). Given the
behavioral complexities of substance use and addiction and that
the global provision of harm reduction services is suboptimal,
structural level interventions, including policy reform processes
that allow for the implementation of comprehensive harm
reduction services, offer signiﬁcant beneﬁt for IDU. In order to
secure policy reform that supports such interventions, policy-
makers, their constituencies, and SEP providers must overcome a
number of legal barriers.
Although there is empirical evidence that SEPs do not increase
substance use, crime, or the numbers of discarded syringes found
in public locations (e.g., streets, parks) (Watters et al., 1994; Wodak
& Cooney, 2006; Wodak & Mcleod, 2008), policy change discus-
sions related to their implementation may be clouded by
community stakeholder fears and concerns. These discussions
may beneﬁt from policymakers’ utilization of research evidence as
a means to dispel reservations about implementing syringe
exchange services. Unfortunately, research evidence may be
underutilized by policymakers and is subject to a range of factors
that inﬂuence its utilization (Brownson et al., 2006; Davis &
Howden-chapman, 1996; Edwards, 2005; Frenk, 1992; Hanney
et al., 2003; Nutley et al., 2003; Ritter, 2011; Trostle et al., 1999).
Further complicating the issue is the fact that policymakers must
take into account the amount of political capital available for
advancing policies and how to achieve compromise among the
legislature (Brownson et al., 2006).
In light of the complexities of applying research evidence to
policy change processes, it is important to determine how and in
what context research evidence is used by policy stakeholders in
legislative reform processes for the expansion of structural-level
interventions for public health. There are a number of frameworks
in the public health literature that have been used to describe this
process. Of greatest relevance to the example of harm reductionand, more speciﬁcally, syringe exchange, is the operationalization
framework provided by Weiss et al., who state research evidence
can be applied to the policy change process in three ways –
instrumentally, conceptually, or symbolically – or not at all (Weiss,
Graham, & Birkeland, 2005). These typologies, and variants of
them, are frequently referenced in health policy and evaluation
research (Amara, Ouimet, & Landry, 2004; Cousins & Leithwood,
1986; Field, Gauld, & Lawrence, 2012; Greene, 1988; Landry,
Amara, & Lamari, 2001; Lavis et al., 2002; Leviton & Hughes, 1981;
NRC, 2012; Turnbull, 1998; Weiss & Weiss, 1981; Weiss et al.,
2005; Weiss, 1979).
When research evidence is applied in an instrumental manner
to policy change processes, it forms the basis of decision making
and gives direction to policy (Weiss et al., 2005). However, research
has found that policymakers rarely apply research evidence
exclusively in an instrumental manner and that they view
instrumental use as only one way in which research can be used
in policy development (Weiss & Weiss, 1981); for example, a study
among professionals and managers in Canadian and provincial
government agencies found that multiple applications of research
evidence simultaneously played a role in the agencies (Amara et al.,
2004). The lack of exclusive instrumental application of research
evidence may be explained by the fact that research must be
negotiated in the contexts of other competing factors in the policy
change environment and that its effectiveness is dependent on the
contextual factors surrounding the legislative body, such as the
willingness of policymakers to rely on evidence in policy processes.
Conceptual use of research evidence occurs indirectly when
evidence diffuses into the population and, overtime, inﬂuences
policy processes by changing ideas and understandings (Weiss
et al., 2005). This application of research evidence may be
especially useful for understanding policy change processes
related to HIV prevention for IDU due to the stigmatized nature
of the population (i.e. conceptual shifts in perceptions of IDU may
be required for policies to advance that are not biased by
stigmatization). The importance of the conceptual understanding
of a problem in policy processes was illustrated by a study that
suggested methadone maintenance therapy (MMT) signiﬁed
different ideas among policy change actors (e.g. MMT was viewed
as a manifestation of cynicism and misanthropy or as a logical
strategy to combat problems stemming from addiction) (Johnson &
Hagstrom, 2005). In scenarios pertaining to IDU health, such as
changing policies for the implementation of SEPs, conceptual
applications of research evidence may offer great value by shifting
how addiction and treatment of addiction is understood among the
legislature.
Symbolic use of research evidence occurs when stakeholders use
evidence as a means to provide legitimization for preexisting
preferences and actions (Weiss et al., 2005). Evidence can be used to
justify policies that were created based on intuition or speciﬁc
personal or organizational interests (Weiss et al., 2005). Symbolic
applications of research evidence may be of notable relevance to
situations where policy changes are necessary to advance the health
and well-being of marginalized populations (such as IDU) or address
health issues (e.g., mental illness, substance use, and addiction) that
are stigmatized and/or misunderstood – and therefore not
supported – by the general constituency. In these scenarios, political
leaders may apply research evidence symbolically as a means of
justifying policy decisions to their constituents. According to Weiss
et al., these typologies ‘‘capture much of the experience in the
empirical literature and practical experience’’ in the role of research
evidence in shaping health policies (Weiss et al., 2005).
Although existing literature has documented how policymakers
access research evidence and barriers to its utilization (Brownson
et al., 2006, 2009; Ritter, 2009), surprisingly little work has been
done to examine how research evidence has been utilized in the
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impeded harm reduction services for IDU. We applied Weiss et al’s
operationalizations (Weiss et al., 2005) of these typologies in our
framework for understanding how research evidence was used in
reform processes for the implementation of publicly funded
syringe exchange programs for HIV prevention in three US cities:
Baltimore, MD, Philadelphia, PA, and Washington, DC. The three
study cities were selected due to the comparability of their political
obstacles to the implementation of publicly funded SEPs.
In both Philadelphia and Baltimore, existing drug paraphernalia
laws prevented the cities from engaging in syringe exchange; in
Washington, DC, the issue surrounding implementation of syringe
exchange was tied to Federal oversight of municipal funds. In
Pennsylvania, state-level laws (including the Pennsylvania Drug
Paraphernalia Act of 1980) criminalized the selling, distribution
and possession of items considered ‘‘drug paraphernalia’’ (Burris,
2000). With the passage of Executive Order 4-92 in 1992 (City of
Philadelphia, 2015), Philadelphia was able to legally implement
syringe exchange with no further legislative obstacles. Baltimore
had a similar legislative impediment in the form of the Maryland
Uniform Controlled Dangerous Substances Act, which made the
possession of drug paraphernalia – including hypodermic syringes
– illegal (MGALM, 2015). Similar to Pennsylvania, Maryland passed
SB 402 in 1994 that legalized SEP operations (MGA, 2015).
For DC, the hurdle to SEP implementation was both legislative
and ﬁnancial. Since the District of Columbia is not a state, Congress
must approve its municipal budgets; this process of budget
approval is partly addressed in the Financial Services Appropria-
tions Bill, which is voted on by the Senate and House Committees
on Appropriations. In addition to the prohibition on the use of
Federal funds for SEPs that was implemented in 1988 (US Congress,
2015a), the Financial Services Appropriations Bill passed by
Congress in 1998 included language that prohibited the District
of Columbia from using municipal revenue to support syringe
exchange services (US Congress, 2015b). This restriction remained
in place until 2007, when the Financial Service Appropriations Bill
governing DC’s expenditures was ﬁnally passed without the rider
prohibiting SEP funding (US Congress, 2015c), Despite the various
legislative barriers, each of the study cities was successful in
securing policy change for the implementation of publicly funded
SEPs, partially through stakeholders’ utilization of research
evidence in the policy change processes.
We address the deﬁcits in the literature pertaining to the role of
research evidence in policy change processes for syringe access
through qualitative interviews with policy change stakeholders in
each study city. These interviews explored how political climates,
perceptions of the HIV epidemic, and willingness to embrace harm
reduction strategies merged with research evidence to achieve policy
reform for SEP implementation. Examination of the interviews
through the lens of typological applications of research evidence was
used to understand the role of research evidence in securing policy
change in each city. We hypothesized that applications of research
evidence to policy change processes would be varied between the
cities based on the conceptual and philosophical understandings
policymakers had toward substance use and addiction, and their
willingness to integrate empirical ﬁndings into policy change
processes. In examining this hypothesis, we provide insights into
how research evidence may be used in a global context to secure
policy change in support of harm reduction services.
Methods
The study cities (Baltimore, MD, Philadelphia, MD, and
Washington, DC) were selected for this research because policy
changes were required in each city before municipal funds could be
utilized for SEP implementation. In each case, the research base forthe effectiveness of syringe exchange for HIV prevention had
already been established and policymakers and advocates in each
city had access to that evidence.
Key stakeholder interviews were conducted in each city during
the time period of March 2012 to August 2013. The process for
identifying key stakeholders in each location was completed by
conducting comprehensive searches of published and publicly
available literature (including media reports, city or federal
government proceedings, etc.) pertaining to syringe exchange
during the time period surrounding the policy change in each city.
Online searches of words related to policy change for the
implementation of publicly funded syringe exchange programs
(e.g. ‘‘syringe exchange policy in Baltimore’’, ‘‘policy change for
syringe exchange in Washington, DC’’, ‘‘opponents of syringe
exchange policy change in Philadelphia’’, etc.) were conducted
using Google. These searches included archives of print media and
legislative documents appropriate to each city. Key stakeholders
were also identiﬁed through respondent driven sampling in that
participants were asked at the end of their interviews to identify
other potential stakeholders who they thought should be
interviewed. These referrals were then vetted against the historical
record for veriﬁcation of their role in the policy change movement
and, if appropriate, contacted for engagement in the study. In order
to obtain a balanced perspective of the policy change process in
each city, great efforts were taken by the research team to ﬁnd both
proponents and opponents of syringe exchange for interviews.
Identiﬁed stakeholders were contacted by phone and e-mail,
informed about the study, and asked to participate. For those
agreeing to participate, appointments were made for either an in-
person interview or a telephone interview (at the preference of the
participant). On the date of the interview and following the
administration of informed consent, participants participated in an
in-depth, semi-structured qualitative interview exploring the
history of needle exchange in stakeholders’ respective cities,
factors leading up to the policy change, how the policy change
occurred, and what role research evidence had in shaping the
legislative processes that led to SEP implementation.
Although the interview script was largely identical for all
participants, the questions were tailored to the respective role of
the study participant at the time of the policy change (e.g., policy
maker, community stakeholder/advocate, etc.). Participants who
had multiple roles throughout the policy change process were
asked questions through the lens of all applicable roles. Each
interview lasted approximately two hours and, at the completion
of the interview, participants were offered $40 as compensation for
their time. All interviews were audio-recorded with the permission
of the participant. Each participant was assigned a unique
identiﬁer that was used to code each interview in order to protect
the participant’s conﬁdentiality.
Completed interviews were transcribed verbatim into NVivo
10 for data management and coding. Two separate qualitative data
coders analyzed the transcripts for any mention of research
evidence. For the purposes of this study, research evidence was
deﬁned as: (1) any mention of empirical studies related to SEPs, (2)
any data that played a role in shaping/driving policy change, (3)
any mention of persons using or not using research evidence, and
(4) any mentions or discussions of how stakeholders employed
research evidence to argue in favor or against SEP implementation.
Disagreements in coding were discussed and resolved. Cohen’s
Kappa was used to check consistency between coders and was
found to be satisfactory (Kappa = 0.83). Exemplar quotes of
research evidence application in each city were then classiﬁed
by the primary author according to the three typologies. This
research was determined by The George Washington University
Institutional Review Board as being exempt from IRB oversight
(IRB # 051106).
Table 1
Participation rate of stakeholders by city and position toward syringe exchange programs.
Baltimore Philadelphia District of Columbia
Support Opposition Support Opposition Support Opposition
Identiﬁed 14 8 13 3 15 3
Could not locate/deceased 3 4 1 0 0 0
Approached 11 4 12 3 10 2
Interviewed 10 0 9 2 8 0
Participation rate 91% 0% 75% 67% 80% 0%
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Examination of historical records and recommendations from
other participants led to the identiﬁcation of stakeholders in
Baltimore (n = 22), Philadelphia (n = 16), and DC (n = 18), who
played a role in the policy change processes associated with securing
publicly funded SEPs in their respective cities. Five stakeholders who
were identiﬁed through either the literature or through recom-
mendations were deceased and three others could not be located.
With the exception of legislative voting records, the majority of the
documents reviewed did not identify speciﬁc persons who were
consistently and/or publicly opposed to SEPs. Table 1 summarizes
the participation rate of stakeholders in the study.
In total, 29 key informants were interviewed (22 in person, 7 by
telephone) between March 2012 and August 2013. The majority of
participants self-identiﬁed their primary role in change processes
as policymakers (52%) followed by 48% who identiﬁed as
advocates. Overall, the majority of participants identiﬁed as Male
(66%) and White/Caucasian (69%). Table 2 summarizes participant
demographics and respective roles in the policy change process.
Baltimore city context
Many stakeholders in Baltimore described the policy change
that allowed SEP implementation in relation to strong political
leaders who were advocates for the application of research
evidence in policy reform processes. Research evidence was
described in terms of how it was actively applied to guide
policymakers in the formation of policies that supported SEP
implementation and as motivation to not give up on the battle to
overcome legislative hurdles. For these reasons, Baltimore
primarily used research evidence in an instrumental manner to
directly facilitate and guide policy change. One interviewee
captured this instrumental use of research evidence as follows:
‘‘. . .I think Maryland was able to . . .fend off bad stuff and make
policy decisions based on science.’’
Policy change detractors were described in terms of their fears
about the potential consequences of SEP implementation. Consis-
tent with the contextual factors at play in other cities during timesTable 2
Demographic characteristics of study participants by city.
Baltimore (n = 10) Philadelphia (n = 1
N % n 
Gender
Male 8 80 7 
Female 2 20 4 
Role
Policymaker 8 80 4 
Advocate 2 20 7 
Race/ethnicity
African American 4 40 1 
White 6 60 8 
Latino/Hispanic 0 0 2 of SEP debate, some Baltimore stakeholders argued that SEP would
increase substance use and crime. In efforts to contain these fears
and uncertainties, research evidence was utilized directly as a
strategy to allay concerns about SEP implementation and guide
policy discussions to focus on the empirical evidence of SEP
efﬁcacy. The following quotes captured this instrumental research
evidence application by SEP advocates to dispel fears about syringe
exchange activities:
‘‘I think what that did was let the science drive the policy
discussion rather than a lot of fear mongering. . .’’
‘‘. . .There was this AIDS Taskforce driven by the Science. . . . . .so
it was a convergence [of research evidence] at a very uncertain
time.’’
‘‘. . .and part of it was, what’s the empirical evidence, and what, I
think it was important for the mayor and the health department
to say, ‘look, this is controversial, there are a lot of questions
about this, let’s accumulate whatever evidence there is.’’’
Though the Baltimore interviews frequently suggested that
research evidence played a critical role in driving policy change for
the implementation of SEPs, these descriptions primarily occurred
in the contexts of their relationship with policy change supporters
who were research evidence champions, i.e., persons who were
advocates for the utilization of evidence in shaping policy change
for the implementation of SEP services. These champions
predominantly had backgrounds in the medical and public health
sector and, as such, had familiarity with accessing and interpreting
scientiﬁc data. To that end, they used research evidence as a tool to
dispel myths about syringe exchange among policymakers and
their respective constituencies and to guide evidence-based
conclusions about the implications of SEP implementation. What
was critical to this effort was that these champions took the time to
understand why Baltimore residents were concerned about SEP
implementation and they used empirical data to address concerns
and directly confront controversy: ‘‘There were a number of
questions that kept popping up, and we would provide, you know,
new studies with evidence.’’1) District of Columbia (n = 8) Total (n = 29)
% n % n %
64 4 50 19 66
36 4 50 10 34
36 3 38 15 52
63 5 63 14 48
9 1 13 6 21
73 6 75 20 69
18 1 13 3 10
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manner to guide advocacy discussions with persons who had
legislative authority to enact policy change. In these discussions,
research evidence was used in ways that facilitated policy-
makers’ support of SEP implementation: ‘‘. . .so it was a very
tough thing for him to adopt. But he felt comfortable enough with
the science. . .’’. With evidence guiding the decision making
processes, policymakers changed legislation in favor of SEP
implementation.
Philadelphia city context
Research evidence was primarily applied symbolically and
conceptually in the Philadelphia city context. Efforts to legalize
SEPs in Philadelphia were largely guided by the local chapter of the
AIDS Coalition to Unleash Power (ACT UP) and other community
activists who, having learned about SEP efﬁcacy from the research
literature and through other harm reduction advocates, embraced
the research evidence from the onset of their engagement in the
policy change process. Unfortunately, grassroots efforts to legalize
SEPs were hindered by politicians who were skeptical of the
efﬁcacy of needle exchange and who were concerned that it would
increase crime and drug use. Study participants explained that,
because activists perceived the legislative environment as unlikely
to change, they felt a moral imperative to act. In doing so, they
created Prevention Point Philadelphia – an underground SEP – in
1991 and began illegal SEP operations. In this case, research
evidence was used symbolically to justify the decision to begin
illegal syringe exchange:
‘‘So we had read a paper on it and we circulated it among the
leadership, and we liked the methodology they had in New
Haven so we said alright, we can give this a try in a more
controlled way.’’
‘‘. . .it was very convincing that the right thing to do, at this point
in time, was to make syringe exchange an intervention’’
The perception that political leaders were unlikely to align their
views about SEP implementation with those of advocates and the
public health literature was the principal motivator for the
conceptual application of research evidence to secure policy
change by SEP supporters. Activists accepted that policy change
may be best achieved by ﬁrst changing public opinion about SEPs
and then empowering constituencies to put political pressure on
legislators to change policy. SEP activists worked with public
health researchers to inform the community about the evidence
supporting SEPs for combating HIV incidence and, in doing so, to
shift people’s understanding of the importance of SEPs. As
community momentum for SEPs increased and activists and
public health researchers continued to point to the validity of
research evidence in support of SEP implementation, political
leaders gave more consideration to policy change. This indirect,
conceptual application of research evidence was illustrated by an
interviewee who stated, ‘‘. . .you educate community, then you
educate constituencies that eventually pressure politicians or, or
vote for politicians’’. A second example of this conceptual
application of research evidence was captured by an interviewee
who explained, ‘‘Actually, one of the things we told the, uh, the
organizers of the needle exchange was to put some articles out
there, try to educate the community, both in English and Spanish’’.
The combination of conceptual and symbolic applications of
research evidence was effective in generating the forward
momentum in the general public to rally the support needed to
legalize the SEP. Politicians and health ofﬁcials received pressurefrom their constituencies to reassess their views about SEP
operation; they also witnessed activists’ utilization of research
evidence (via symbolic applications) to legitimize the illegal SEP
activities. Eventually, applications of research evidence were
successful in securing policy change that allowed for legal SEP
implementation and operation in Philadelphia.
District of Columbia city context
As a Congressionally controlled district, utilization of municipal
resources in the District is decided upon by legislators who are not
elected by DC residents. As such, DC may play host to political
debates that end in the legislature divided along partisan lines. This
was the case for implementation of SEPs in DC. As in the cases of
Baltimore and Philadelphia, Congressional proponents of syringe
access in DC cited the evidence in the research literature that
supported the effectiveness of SEPs in addressing the HIV/AIDS
epidemic:
‘‘. . .the sets of studies that were coming out were very much
showing that needle exchange did reduce HIV. . . . . .we were
citing data that showed that there was no increase in substance
use, and that there was a decrease in HIV among people living
with HIV or among them. Drug users.’’
Interestingly, study participants who were SEP supporters
explained that Congressional opponents of SEP implementation
claimed to utilize research evidence, but that they did so in a way
that enabled them to ‘‘spin’’ the evidence such that it would
support their opposition. For example, opponents’ use of evidence
was described in terms of persons citing evidence out of context,
misinterpreting research ﬁndings, or selectively picking language
from research articles that they thought supported their claims
(‘‘Well, they did ﬁnd words in studies that they thought supported
[needle exchange increasing crime]. . .’’). Although this ﬁnding
does not provide a balanced perspective inclusive of persons who
were in opposition of SEP implementation, it is, nonetheless, a
notable ﬁnding given the consistency with which it was discussed
among the SEP supporters.
The DC context was further complicated by policy change
detractors’ unwillingness to consider research evidence in policy
change discussions. Interviews suggested this unwillingness was
derived from persons’ fears about the implications of SEPs (such as
they would increase crime and illicit drug use) and based on moral
ideologies. The obstinacy of policymakers who were in opposition
of SEPs to consider the research evidence proved to be a signiﬁcant
and dominant theme in the DC context:
‘‘. . .because the evidence was, whether you quoted from
scientiﬁc journals. . .and . . . statistical evidence, from what
was happening across the United States, none of it mattered.’’
‘‘You have to realize that, for some of the opposition, there are
not any facts that are going to win them on policy. . .’’
‘‘It is possibly the most crazy-making thing about this issue
when we. . . were really. . .working full-tilt on it, and having
[Politician] sitting over there saying, ‘I don’t care what the data
say, I won’t have it’.’’
The frustration stemming from this situation was particularly
evident in the comment of one stakeholder, who remarked, ‘‘. . .I
thought, you know, that the science was there, and people would
listen to the science, I don’t think that elected ofﬁcials really always
do that. . .’’.
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SEP services in DC, reform was eventually achieved following a
shift in the political power structure in Congress. In 2007, the
language proscribing the use of municipal revenue to support
syringe exchange services was removed from the Financial
Services Appropriations Bill. Following the signing of the bill by
President GW Bush, the DC Government immediately allocated
funds to the Department of Health for needle exchange and harm
reduction services. Although research evidence played a role in the
DC context for securing policy change, the votes from members of
Congress who supported SEP outnumbered the votes from SEP
opponents. As such, application of research evidence may not have
affected the actual policy change processes in the same magnitude
as it did in the Baltimore and Philadelphia city contexts.
Discussion
The application of research evidence in shaping policy to
support the implementation of SEPs followed three distinct paths
in Baltimore, MD, Philadelphia, PA, and Washington, DC. For
Baltimore and Philadelphia, research evidence played a consistent
role in driving policy change. Baltimore’s process was guided by
research evidence champions who employed evidence in an
instrumental fashion to drive policy change. Research evidence
champions in Baltimore engaged community stakeholders and
policymakers in discussions that were guided by research evidence
and presented the research in ways that allowed for the evidence
to be easily integrated into the broader sociopolitical context and
change processes in the city. In Philadelphia, policy change
stakeholders applied research evidence conceptually and symbol-
ically to generate forward momentum for policy change among the
general public and to legitimize operation of an illegal SEP. The
study ﬁndings for Philadelphia add to the literature surrounding
conceptual applications of research evidence and the framing of
public health issues by providing more support for how conceptual
shifts in understanding complex public health problems are often
necessary to facilitate change processes. In contrast to Baltimore
and Philadelphia, research evidence played a minor role in DC
because some policymakers were unwilling to consider its
application in policy change discussions. The ﬁndings from DC
provide further support to the literature that suggests public
health efforts may manifest different meanings among policy
stakeholders (Johnson & Hagstrom, 2005) and that policymakers
may ignore research evidence completely (Weiss et al., 2005).
A recurring theme in all three cities was the idea of ‘‘data free
zones’’, i.e., the presence of individuals opposed to SEP implemen-
tation but who had no empirical evidence to support their claims
that SEPs were detrimental to society. Although this ﬁnding was
derived primarily from interviews with SEP supporters, it is a
notable ﬁnding given that it emerged as a theme across all of the
study cities. Participants explained that the arguments made by
SEP opponents were often rooted in fears of SEPs increasing drug
use and undermining the War on Drugs. They elaborated that there
was never any mention or evidence of empirical data that was
correctly cited from the literature that supported their claims.
Analyses of the interviews suggests that opponents’ rationale
against harm reduction strategies was primarily focused on
maintaining existing attitudes and beliefs about IDU – which
included the stigmatization of HIV/AIDS and substance use/
addiction – rather than strategically addressing the HIV/AIDS
epidemic with evidence-based approaches (‘‘. . .there was so much
evidence. . . So much scientiﬁc evidence about the effectiveness of
needle exchange for HIV prevention. I can’t say there was any
rational basis for the policy [needle exchange ban]’’). Because the
majority of participants in this research were SEP supporters,
future work should explore the rationale and policy changeperspective of policymakers who were in opposition of SEP
implementation.
Although this research was based in the context of the United
States, it has implications for global harm reduction efforts. As
evidenced by the policy reform processes in the three study cities,
it is critically important that SEP proponents – particularly
community stakeholders – have an understanding of political
processes and environments, the constituency values of policy-
makers, and the role of advocacy in shaping policy change. Even in
the face of expanding HIV epidemics, aligning these factors in
support of policy reform for SEPs may take a great deal of time and
effort and may only yield incremental policy changes (which may
be more politically palatable and more easily secured) rather than
large-scale reform. Evidence of such incrementalism for harm
reduction policy change can be seen in international contexts, such
as the policy changes around substance use that have occurred in
Iran between the early 1980s and the present. In Iran, the approach
to confronting substance use initially emphasized supply-reduc-
tion and criminalization, but evolved into the large scale
implementation of harm reduction programs (Nissaramanesh,
2015; Rahnama et al., 2014; Razzaghi et al., 2006). Research
evidence can be a strong driver of policy change processes, but
advocates must adapt its utilization to the contextual factors at
play in reform processes and set reasonable goals for reform
efforts.
In each of the study cities, policy reform was partially driven by
elected ofﬁcials receiving pressure from their electorate to enact
change; however, in countries where policymakers are appointed,
this pressure may not have the same inﬂuence. In these scenarios,
research evidence may be used by advocates to convince appointed
policymakers that harm reduction services, such as SEPs, are not
only something the community desires but are public health
interventions that make ﬁscal sense via prevention of infectious
diseases, such as HIV and Hepatitis. This is of particular importance
in countries such as Russia, where policy decisions pertaining to
the scale up of harm reduction services are constrained by ﬁnancial
resources, lack of information about harm reduction efﬁcacy, and
the cultural acceptability of harm reduction services (Tkatchenko-
Schmidt, Renton, Gevorgyan, Davydenko, & Atun, 2008). In
scenarios such as these, research evidence may be used to educate
policymakers about the public health and ﬁscal utility of SEPs and
to guide policy reform in ways that align with data-driven public
health practice. Although the provision of research evidence to
policymakers never guarantees policy change, it is an important
and necessary step in policy change processes for both democratic
and non-democratic countries.
There were several strengths and limitations in this study that
should be noted. Despite the expectation that participants would
not be able to remember details of events that occurred (in some
cases) two decades prior, participants had a strong recollection of
the events that unfolded in their cities and of the players involved.
There was strong corroboration of the historical accountings of
policy change for syringe exchange implementation among
interviewees. This allowed for a relatively easy recreation of the
historical contexts at play in each city during the periods of policy
change for SEP implementation. A further strength of this study is
that of balance among participants based on their respective role in
policy change processes. We are conﬁdent our research captured
both the legislative perspective as well as the advocate perspective
on publicly funded syringe exchange program implementation.
The greatest limitation of this study is that some stakeholders
were either not able or not willing to participate in the interview.
Several of the stakeholders who were identiﬁed (either through the
literature review or through recommendation of other partici-
pants) were deceased or unable to be found. Other persons,
primarily opponents of policy change for SEP implementation,
S.T. Allen et al. / International Journal of Drug Policy 26 (2015) 688–695694refused participation. Although great efforts were made to ﬁnd and
interview opponents of policy change, their perspectives were not
necessarily captured by the present study. Despite this limitation,
we feel this study provides valuable insights into the role of
research evidence in policy change processes for SEP implementa-
tion.
In theory, policy reform for public health should be an objective
process that is guided by the values of the electorate, empirical
research evidence, and consideration for what is most feasible and
has a high likelihood of success. Unfortunately, reform processes
can become derailed by policymakers who fail to apply research
evidence to change processes and by persons who apply empirical
study ﬁndings incorrectly or out of context. As applied to HIV
prevention, changing public policy to facilitate or expand the
impact of structural interventions, such as SEPs, can signiﬁcantly
reduce HIV risk for many vulnerable populations. Advocates and
community stakeholders seeking to change policies to beneﬁt
public health may be well served by better understanding the
sociopolitical and contextual factors of their legislature and how
research evidence can be integrated into change processes. The
correct and timely utilization of research evidence can serve to
build a stronger foundation for how public health issues and
prevention strategies are understood among and addressed by
policymakers and their constituencies.
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